Active
On

Fund Radar: Pharma companies regain their growth trajectory

Pharmaceutical companies were once known for their strong growth potential, but slowing revenue growth, lower valuations, and higher dividend yields have given them a more mixed profile in recent years. However, over the past three years, Novo Nordisk and Eli Lilly have stood out by reclaiming their growth status.

European equities: The rise of the ‘Granolas’

In the US, a select group of seven stocks have garnered much attention since last year for their impact on stock market performance. This illustrious group, known as the Magnificent Seven, includes Microsoft, Apple, Alphabet, Amazon, Nvidia, Meta, and Tesla. Collectively, these tech giants accounted for 32.5 percent of the S&P 500 index as of the end of April 2024.

Emerging markets lag behind, but not at GQG Partners

Emerging markets continued last year’s trend in Q1 2024. And that is not good news for emerging market investors, as it meant another significant underperformance versus developed countries. Although the return of the MSCI EM index was 4.71 per cent in euros, making it positive in absolute terms, it is a considerably worse result than the 11.37 per cent achieved by the MSCI World index.

Top 5: UBS gold mine tracker leads precious metals funds

In a turbulent year like 2022, investors needed refuge, which was almost nowhere to find. Investments in oil showed outstanding performance, as one of the few areas in the financial markets. And then there were precious metals. Not all metals performed equally well though, and positive returns were mostly measured in euros.